Rep. Julia Letlow Buys AstraZeneca PLC (NASDAQ:AZN) Shares

Representative Julia Letlow (R-Louisiana) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on January 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on December 8th. The trade occurred in the Representative’s “MERRILL LYNCH INVESTMENT ACCOUNT #025” account.

Representative Julia Letlow also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Pinterest (NYSE:PINS) on 12/16/2025.
• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Mettler-Toledo International (NYSE:MTD) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Icon Energy (NASDAQ:ICON) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Warner Bros. Discovery (NASDAQ:WBD) on 12/8/2025.

AstraZeneca Stock Up 1.9%

Shares of NASDAQ AZN opened at $96.34 on Thursday. The firm has a market cap of $298.79 billion, a price-to-earnings ratio of 32.01, a price-to-earnings-growth ratio of 1.56 and a beta of 0.34. The company’s 50-day simple moving average is $91.12 and its 200-day simple moving average is $82.50. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $96.51.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The firm had revenue of $15.19 billion for the quarter, compared to analyst estimates of $14.75 billion. During the same period last year, the company posted $2.08 EPS. AstraZeneca’s quarterly revenue was up 12.0% compared to the same quarter last year. Equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AZN. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. HSBC reissued a “buy” rating and issued a $108.00 price objective on shares of AstraZeneca in a research note on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Finally, Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $95.75.

Institutional Trading of AstraZeneca

A number of hedge funds and other institutional investors have recently modified their holdings of AZN. Binnacle Investments Inc grew its holdings in shares of AstraZeneca by 21.8% in the third quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock valued at $51,000 after purchasing an additional 118 shares during the period. Chapin Davis Inc. raised its stake in AstraZeneca by 3.3% during the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after purchasing an additional 120 shares during the period. 44 Wealth Management LLC boosted its holdings in AstraZeneca by 0.7% in the 3rd quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock valued at $1,283,000 after purchasing an additional 124 shares during the last quarter. CoreCap Advisors LLC grew its stake in shares of AstraZeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock valued at $41,000 after buying an additional 125 shares during the period. Finally, Highline Wealth Partners LLC increased its holdings in shares of AstraZeneca by 32.0% during the 3rd quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after buying an additional 129 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

About Representative Letlow

Julia Letlow (Republican Party) is a member of the U.S. House, representing Louisiana’s 5th Congressional District. She assumed office on April 14, 2021. Her current term ends on January 3, 2027.

Letlow (Republican Party) is running for re-election to the U.S. House to represent Louisiana’s 5th Congressional District. She declared candidacy for the primary scheduled on November 3, 2026.

Julia Letlow earned a doctorate. Letlow’s career experience includes working as a senior administrator with the University of Louisiana at Monroe.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.